A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients

Abstract only

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 32; no. 15_suppl; p. 8051
Main Authors Sequist, Lecia V., Lopez-Chavez, Ariel, Doebele, Robert Charles, Gray, Jhanelle Elaine, Harb, Wael A., Modiano, Manuel R., Jackman, David Michael, Baggstrom, Maria Quintos, Atmaca, Akin, Felip, Enriqueta, Provencio, Mariano, Cobo, Manuel, Kripas, Christopher J., MacBeath, Gavin, Czibere, Akos Gabor, Cho, Byoung Chul, Park, Keunchil, Shepherd, Frances A.
Format Journal Article
LanguageEnglish
Published 20.05.2014
Online AccessGet full text

Cover

More Information
Summary:Abstract only
ISSN:0732-183X
1527-7755
DOI:10.1200/jco.2014.32.15_suppl.8051